Evolution of drug resistance in Candida albicans

Annual Review of Microbiology

Volumn 56, Issue , 2002, Pages 139-165

  Cowen, Leah E ^a   Anderson, James B ^a   Kohn, Linda M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adaptation; Experimental evolution; Genomics; HIV; Saccharomyces cerevisiae

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CYTOCHROME P450; ERGOSTEROL; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; LANOSTEROL; MICONAZOLE; PYRROLE DERIVATIVE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; CANDIDA ALBICANS; CELL WALL; DRUG RESISTANCE; FUNGAL GENETICS; FUNGAL METABOLISM; FUNGUS ISOLATION; FUNGUS MUTATION; LIFE CYCLE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EVOLUTION; MULTIDRUG RESISTANCE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW; SACCHAROMYCES CEREVISIAE;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; DRUG RESISTANCE, FUNGAL; EVOLUTION; GENOMICS; HUMANS; MUTATION; MYCOSES;

ANIMALIA; CANDIDA; CANDIDA ALBICANS; FUNGI; SACCHAROMYCES; SACCHAROMYCES CEREVISIAE;

EID: 0036403772     PISSN: 00664227     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.micro.56.012302.160907     Document Type: Review

References (147)

1. Alexander BD, Perfect JR. 1997. Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches. Drugs 54:657-78
2. Anderson JB, Kohn LM. 1998. Genotyping, gene genealogies, and genomics bring fungal population genetics above ground. Trends Ecol. Evol. 13:444-49
3. Anderson JB, Wickens C, Khan M, Cowen LE, Federspiel N, et al. 2001. Infrequent genetic exchange and recombination in the mitochondrial genome of Candida albicans. J. Bacteriol. 183:865-72
4. Arjan JA, Visser M, Zeyl CW, Gerrish PJ, Blanchard JL, Lenski RE. 1999. Diminishing returns from mutation supply rate in asexual populations. Science 283:404-6
5. Austin DJ, Kakehashi M, Anderson RM. 1997. The transmission dynamics of antibiotic-resistant bacteria: The relationship between resistance in commensal organisms and antibiotic consumption. Proc. R. Soc. London Ser. B 264:1629-38
6. Austin DJ, Kristinsson KG, Anderson RM. 1999. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc. Natl. Acad. Sci. USA 96:1152-56
7. Avise JC, Wollenberg K. 1997. Phylogenetics and the origin of species. Proc. Natl. Acad. Sci. USA 94:7748-55
8. Baldauf SL, Roger AJ, Wenk-Siefert I, Doolittle WF. 2000. A kingdom-level phylogeny of eukaryotes based on combined protein data. Science 290:972-77
9. Barchiesi F, Calabrese D, Sanglard D, Falconi Di Francesco L, Caselli F, et al. 2000. Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. Antimicrob. Agents Chemother. 44:1578-84
10. Bektic J, Lell CP, Fuchs A, Stoiber H, Speth C, et al. 2001. HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro. FEMS Immunol. Med. Microbiol. 31:65-71
11. Bergstrom CT, McElhany P, Real LA. 1999. Transmission bottlenecks as determinants of virulence in rapidly evolving pathogens. Proc. Natl. Acad. Sci. USA 96:5095-100
12. Binswanger HP. 2001. Public health. HIV/AIDS treatment for millions. Science 292:221-23
13. Björkman J, Andersson DI. 2000. The cost of antibiotic resistance from a bacterial perspective. Drug Resist. Updates 3:237-45
14. Bonhoeffer S, Lipsitch M, Levin BR. 1997. Evaluating treatment protocols to prevent antibiotic resistance. Proc. Natl. Acad. Sci. USA 94:12106-11
15. Bonhoeffer S, May RM, Shaw GM, Nowak MA. 1997. Virus dynamics and drug therapy. Proc. Natl. Acad. Sci. USA 94:6971-76
16. Bull JJ, Badgett MR, Wichman HA. 2000. Big-benefit mutations in a bacteriophage inhibited with heat. Mol. Biol. Evol. 17:942-50
17. Burch CL, Chao L. 2000. Evolvability of an RNA virus is determined by its mutational neighbourhood. Nature 406:625-28
18. Calabrese D, Bille J, Sanglard D. 2000. A novel multidrug efflux transporter gene of the major facilitator superfamily from Candida albicans (FLU1) conferring resistance to fluconazole. Microbiology 146:2743-54
19. Cassone A, De Bernardis F, Torosantucci A, Tacconelli E, Tumbarello M, Cauda R. 1999. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J. Infect. Dis. 180:448-53
20. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. 2001. Biofilm formation by the fungal pathogen Candida albicans: Development, architecture, and drug resistance. J. Bacteriol. 183:5385-94
21. Coleman DC, Rinaldi MG, Haynes KA, Rex JH, Summerbell RC, et al. 1998. Importance of Candida species other than Candida albicans as opportunistic pathogens. Med. Mycol. 36:156-65
22. Cooper VS, Lenski RE. 2000. The population genetics of ecological specialization in evolving Escherichia coli populations. Nature 407:736-39
23. Cowen LE. 2001. Predicting the emergence of resistance to antifungal drugs. FEMS Microbiol. Lett. 204:1-7
24. Cowen LE, Kohn LM, Anderson JB. 2001. Divergence in fitness and evolution of drug resistance in experimental populations of Candida albicans. J. Bacteriol. 183:2971-78
25. Cowen LE, Nantel A, Whiteway MS, Thomas DY, Tessier DC, et al. 2002. Population genomics of drug resistance in Candida albicans. Proc. Natl. Acad. Sci. USA 99:9284-89
26. Cowen LE, Sanglard D, Calabrese D, Sirjusingh C, Anderson JB, Kohn LM. 2000. Evolution of drug resistance in experimental populations of Candida albicans. J. Bacteriol. 182:1515-22
27. Cowen LE, Sirjusingh C, Summerbell RC, Walmsley S, Richardson S, et al. 1999. Multilocus genotypes and DNA fingerprints do not predict variation in azole resistance among clinical isolates of Candida albicans. Antimicrob. Agents Chemother. 43:2930-38
28. Crill WD, Wichman HA, Bull JJ. 2000. Evolutionary reversals during viral adaptation to alternating hosts. Genetics 154:27-37
29. De Backer MD, Magee PT, Pla J. 2000. Recent developments in molecular genetics of Candida albicans. Annu. Rev. Microbiol. 54:463-98
30. DiDomenico B. 1999. Novel antifungal drugs. Curr. Opin. Microbiol. 2:509-15
31. Dismukes WE. 2000. Introduction to antifungal drugs. Clin. Infect. Dis. 30:653-57
32. Dupont B, Crewe Brown HH, Westermann K, Martins MD, Rex JH, et al. 2000. Mycoses in AIDS. Med. Mycol. 38:259-67
33. Dybul M, Chun TW, Yoder C, Hidalgo B, Belson M, et al. 2001. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters. Proc. Natl. Acad. Sci. USA 98:15161-66
34. Edwards JE Jr. 2001. Management of severe candidal infections: Integration and review of current guidelines for treatment and prevention. Curr. Clin. Top. Infect. Dis. 21:135-47
35. Eigen M. 1987. New concepts for dealing with the evolution of nucleic acids. Cold Spring Harbor Symp. Quant. Biol. 52:307-20
36. Forche A, Schönian G, Gräser Y, Vilgalys R, Mitchell TG. 1999. Genetic structure of typical and atypical populations of Candida albicans from Africa. Fungal Genet. Biol. 28:107-25
37. Franz R, Kelly SL, Lamb DC, Kelly DE, Ruhnke M, Morschhauser J. 1998. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob. Agents Chemother. 42:3065-72
38. Garcia-Lerma JG, Heneine W. 2001. Resistance of human immunodeficiency virus type 1 to reverse transcriptase and protease inhibitors: Genotypic and phenotypic testing. J. Clin. Virol. 21:197-212
39. Georgopapadakou NH. 1998. Antifungals: Mechanism of action and resistance, established and novel drugs. Curr. Opin. Microbiol. 1:547-57
40. Georgopapadakou NH. 2001. Update on antifungals targeted to the cell wall: Focus on beta-1,3-glucan synthase inhibitors. Expert Opin. Invest. Drugs 10:269-80
41. Georgopapadakou NH, Walsh TJ. 1994. Human mycoses: Drugs and targets for emerging pathogens. Science 264:371-73
42. Gerrish PJ, Lenski RE. 1998. The fate of competing beneficial mutations in an asexual population. Genetica 103:127-44
43. Ghannoum MA. 1996. Is antifungal susceptibility testing useful in guiding fluconazole therapy? Clin. Infect. Dis. 22: S161-65
44. Ghannoum MA, Rex JH, Galgiani JN. 1996. Susceptibility testing of fungi: Current status of correlation of in vitro data with clinical outcome. J. Clin. Microbiol. 34:489-95
45. Giaever G, Shoemaker DD, Jones TW, Liang H, Winzeler EA, et al. 1999. Genomic profiling of drug sensitivities via induced haploinsufficiency. Nat. Genet. 21:278-83
46. Goldstein AL, McCusker JH. 2001. Development of Saccharomyces cerevisiae as a model pathogen. A system for the genetic identification of gene products required for survival in the mammalian host environment. Genetics 159:499-513
47. Gräser Y, Volovsek M, Arrington J, Schönian G, Presber W, et al. 1996. Molecular markers reveal that population structure of the human pathogen Candida albicans exhibits both clonality and recombination. Proc. Natl. Acad. Sci. USA 93:12473-77
48. Gubbins S, Gilligan CA. 1999. Invasion thresholds for fungicide resistance: Deterministic and stochastic analyses. Proc. R. Soc. London Ser. B 266:2539-49
49. Hall BG. 1999. Toward an understanding of evolutionary potential. FEMS Microbiol. Lett. 178:1-6
50. Hartman JL, Garvik B, Hartwell L. 2001. Principles for the buffering of genetic variation. Science 291:1001-4
51. Hermans P. 2001. Current review and clinical management of patients with primary HIV-1 infection: Limits and perspectives. Biomed. Pharmacother. 55:301-7
52. Hull CM, Raisner RM, Johnson AD. 2000. Evidence for mating of the "asexual" yeast Candida albicans in a mammalian host. Science 289:307-10
53. Klepser ME, Lewis RE, Pfaller MA. 1998. Therapy of Candida infections: Susceptibility testing, resistance, and therapeutic options. Ann. Pharmacother. 32:1353-61
54. Kolaczkowska A, Goffeau A. 1999. Regulation of pleiotropic drug resistance in yeast. Drug Resist. Updates 2:403-14
55. Kondrashov FA, Kondrashov AS. 2001. Multidimensional epistasis and the disadvantage of sex. Proc. Natl. Acad. Sci. USA 98:12089-92
56. Korona R. 1999. Unpredictable fitness transitions between haploid and diploid strains of the genetically loaded yeast Saccharomyces cerevisiae. Genetics 151:77-85
57. Korting HC, Schaller M, Eder G, Hamm G, Bohmer U, Hube B. 1999. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. Antimicrob. Agents Chemother. 43:2038-42
58. Lamb D, Kelly D, Kelly S. 1999. Molecular aspects of azole antifungal action and resistance. Drug Resist. Updates 2:390-402
59. Lata Panwar S, Krishnamurthy S, Gupta V, Alarco AM, Raymond M, et al. 2001. CaALK8, an alkane assimilating cytochrome P450, confers multidrug resistance when expressed in a hypersensitive strain of Candida albicans. Yeast 18:1117-29
60. Lengeler KB, Davidson RC, D'Souza C, Harashima T, Shen WC, et al. 2000. Signal transduction cascades regulating fungal development and virulence. Microbiol. Mol. Biol. Rev. 64:746-85
61. Lengeler KB, Wang P, Cox GM, Perfect JR, Heitman J. 2000. Identification of the MATa mating-type locus of Cryptococcus neoformans reveals a serotype A MATa strain thought to have been extinct. Proc. Natl. Acad. Sci. USA 97:14455-60
62. Lenski RE. 1993. Assessing the genetic structure of microbial populations. Proc. Natl. Acad. Sci. USA 90:4334-36
63. Lenski RE, Mongold JA, Sniegowski PD, Travisano M, Vasi F, et al. 1998. Evolution of competitive fitness in experimental populations of E. coli: What makes one genotype a better competitor than another? Antonie Van Leeuwenhoek 73:35-47
64. Lenski RE, Travisano M. 1994. Dynamics of adaptation and diversification: A 10,000-generation experiment with bacterial populations. Proc. Natl. Acad. Sci. USA 91:6808-14
65. Levin BR. 2001. Minimizing potential resistance: A population dynamics view. Clin. Infect. Dis. 33:S161-69
66. Levin BR, Bergstrom CT. 2000. Bacteria are different: Observations, interpretations, speculations, and opinions about the mechanisms of adaptive evolution in prokaryotes. Proc. Natl. Acad. Sci. USA 97:6981-85
67. Levin BR, Lipsitch M, Bonhoeffer S. 1999. Population biology, evolution, and infectious disease: Convergence and synthesis. Science 283:806-9
68. Levin BR, Perrot V, Walker N. 2000. Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Genetics 154:985-97
69. Lipsitch M, Bergstrom CT, Levin BR. 2000. The epidemiology of antibiotic resistance in hospitals: Paradoxes and prescriptions. Proc. Natl. Acad. Sci. USA 97:1938-43
70. Lorenz MC, Fink GR. 2001. The glyoxylate cycle is required for fungal virulence. Nature 412:83-86
71. Lott TJ, Effat MM. 2001. Evidence for a more recently evolved clade within a Candida albicans North American population. Microbiology 147:1687-92
72. Lott TJ, Holloway BP, Logan DA, Fundyga R, Arnold J. 1999. Towards understanding the evolution of the human commensal yeast Candida albicans. Microbiology 145:1137-43
73. Luria SE, Delbruck M. 1943. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 28:491-511
74. Luu LN, Cowen LE, Sirjusingh C, Kohn LM, Anderson JB. 2001. Multilocus genotyping indicates that the ability to invade the bloodstream is widespread among Candida albicans isolates. J. Clin. Microbiol. 39:1657-60
75. Mable BK, Otto SP. 2001. Masking and purging mutations following EMS treatment in haploid, diploid and tetraploid yeast (Saccharomyces cerevisiae). Genet. Res. 77:9-26
76. Magee BB, Magee PT. 2000. Induction of mating in Candida albicans by construction of MTLa and MTLalpha strains. Science 289:310-13
77. Marton MJ, DeRisi JL, Bennett HA, Iyer VR, Meyer MR, et al. 1998. Drug target validation and identification of secondary drug target effects. Nat. Med. 4:1293-301
78. McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, et al. 2001. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin. Infect. Dis. 33:641-47
79. Milgroom MG. 1990. A stochastic model for the initial occurrence and development of fungicide resistance in plant pathogen populations. Phytopathology 80:410-16.
80. Mitchell AP. 1998. Dimorphism and virulence in Candida albicans. Curr. Opin. Microbiol. 1:687-92
81. Morison L. 2001. The global epidemiology of HIV/AIDS. Br. Med. Bull. 58:7-18
82. Nguyen MH, Peacock JJ, Morris AJ, Tanner DC, Nguyen ML, et al. 1996. The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance. Am. J. Med. 100:617-23
83. Odds FC. 2000. Pathogenic fungi in the 21st century. Trends Microbiol. 8:200-1
84. Odds FC, Gow NA, Brown AJ. 2001. Fungal virulence studies come of age. Genome Biol. 2: reviews 1009.1-1009.4
85. Orr HA. 1999. The evolutionary genetics of adaptation: A simulation study. Genet. Res. 74:207-14
86. Otto SP, Barton NH. 2001. Selection for recombination in small populations. Evolution 55:1921-31
87. Paquin CE, Adams J. 1983. Relative fitness can decrease in evolving asexual populations of S. cerevisiae. Nature 306:368-71
88. Pennisi E. 2001. The push to pit genomics against fungal pathogens. Science 292:2273-74
89. Perepnikhatka V, Fischer FJ, Niimi M, Baker RA, Cannon RD, et al. 1999. Specific chromosome alterations in fluconazole-resistant mutants of Candida albicans. J. Bacteriol. 181:4041-49
90. Perfect JR, Cox GM. 1999. Drug resistance in Cryptococcus neoformans. Drug Resist. Updates 2:259-69
91. Pfaller MA. 1998. The epidemiology of invasive mycoses - Narrowing the gap. Clin. Infect. Dis. 27:1148-50
92. Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, et al. 2001. International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J. Clin. Microbiol. 39:3254-59
93. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. 1998. National surveillance of nosocomial bloodstream infection due to Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn. Microbiol. Infect. Dis. 31:327-32
94. Pfaller MA, Lockhart SR, Pujol C, Swails WJ, Messer SA, et al. 1998. Hospital specificity, region specificity, and fluconazole resistance of Candida albicans bloodstream isolates. J. Clin. Microbiol. 36:1518-29
95. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, et al. 1999. Trends in species distribution and susceptibility to fluconazole among bloodstream isolates of Candida species in the United States. Diagn. Microbiol. Infect. Dis. 33:217-22
96. Pinner RW, Teutsch SM, Simonsen L, Klug LA, Graber JM, et al. 1996. Trends in infectious diseases mortality in the United States. JAMA 275:189-93
97. Pujol C, Reynes J, Renaud F, Raymond M, Tibayrenc M, et al. 1993. The yeast Candida albicans has a clonal mode of reproduction in a population of infected human immunodeficiency virus-positive patients. Proc. Natl. Acad. Sci. USA 90:9456-59
98. Rainey PB, Buckling A, Kassen R, Travisano M. 2000. The emergence and maintenance of diversity: Insights from experimental bacterial populations. Trends Ecol. Evol. 15:243-47
99. Rainey PB, Travisano M. 1998. Adaptive radiation in a heterogeneous environment. Nature 394:69-72
100. Ramage G, VandeWalle K, Wickes BL, Lopez-Ribot JL. 2001. Characteristics of biofilm formation by Candida albicans. Rev. Iberoam. Micol. 18:163-70
101. Ramage G, Wickes BL, Lopez-Ribot JL. 2001. Biofilms of Candida albicans and their associated resistance to antifungal agents. Am. Clin. Lab. 20:42-44
102. Rangel-Frausto MS, Wiblin T, Blumberg HM, Saiman L, Patterson J, et al. 1999. National epidemiology of mycoses survey (NEMIS): Variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin. Infect. Dis. 29:253-58
103. Raymond M, Dignard D, Alarco AM, Clark KL, Weber S, et al. 2000. Molecular cloning of the CRM1 gene from Candida albicans. Yeast 16:531-38
104. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, et al. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro/in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-47
105. Rex JH, Pfaller MA, Walsh TJ, Chaturvedi V, Espinel-Ingroff A, et al. 2001. Antifungal susceptibility testing: Practical aspects and current challenges. Clin. Microbiol. Rev. 14:643-58
106. Rex JH, Rinaldi MG, Pfaller MA. 1995. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39:1-8
107. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, et al. 2000. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin. Infect. Dis. 30:662-78
108. Reyes G, Ghannoum MA. 2000. Antifungal susceptibility testing of yeasts: Uses and limitations. Drug Resist. Updates 3:14-19
109. Rose MR, Lauder GV, eds. 1996. Adaptation. San Diego: Academic. 511 pp.
110. Rosewich U, Kistler H. 2000. Role of horizontal gene transfer in the evolution of fungi. Annu. Rev. Phytopathol. 38 3 8:325-63
111. Ruiz-Diez B, Martinez V, Alvarez M, Rodriguez-Tudela JL, Martinez-Suarez TV. JV. 1997. Molecular tracking of Candida albicans in a neonatal intensive care unit: Long-term colonizations versus catheter-related infections. J. Clin. Microbiol. 35:3032-36
112. Sanglard D. 2001. Integrated antifungal drug discovery in Candida albicans. Nat. Biotechnol. 19:212-13
113. Sanglard D, Ischer F, Calabrese D, de Micheli M, Bille J. 1998. Multiple resistance mechanisms to azole antifungals in yeast clinical isolates. Drug Resist. Updates 1:255-65
114. Sheehan DJ, Hitchcock CA, Sibley CM. 1999. Current and emerging azole antifungal agents. Clin. Microbiol. Rev. 12:40-79
115. Sniegowski P. 1999. The genomics of adaptation in yeast. Curr. Biol. 9:R897-98
116. Sniegowski PD, Gerrish PJ, Johnson T, Shaver A. 2000. The evolution of mutation rates: Separating causes from consequences. Bioessays 22:1057-66
117. Sniegowski PD, Gerrish PJ, Lenski RE. 1997. Evolution of high mutation rates in experimental populations of E. coli. Nature 387:703-5
118. Stemmer WP. 1994. Rapid evolution of a protein in vitro by DNA shuffling. Nature 370:389-91
119. Talibi D, Raymond M. 1999. Isolation of a putative Candida albicans transcriptional regulator involved in pleiotropic drug resistance by functional complementation of a pdr1 pdr3 mutation in Saccharomyces cerevisiae. J. Bacteriol. 181:231-40
120. Taylor JW, Geiser DM, Burt A, Koufopanou V. 1999. The evolutionary biology and population genetics underlying fungal strain typing. Clin. Microbiol. Rev. 12:126-46
121. Taylor JW, Jacobson DJ, Kroken S, Kasuga T, Geiser DM, et al. 2000. Phylogenetic species recognition and species concepts in fungi. Fungal Genet. Biol. 31:21-32
122. Taylor M, Feyereisen R. 1996. Molecular biology and evolution of resistance to toxicants. Mol. Biol. Evol. 13:719-34
123. Tibayrenc M. 1997. Are Candida albicans natural populations subdivided? Trends Microbiol. 5:253-54
124. Tkacz JS, DiDomenico B. 2001. Antifungals: What's in the pipeline. Curr. Opin. Microbiol. 4:540-45
125. Travisano M. 2001. Evolution: Towards a genetical theory of adaptation. Curr. Biol. 11:R440-42
126. Travisano M, Mongold JA, Bennett AF, Lenski RE. 1995. Experimental tests of the roles of adaptation, chance, and history in evolution. Science 267:87-90
127. Tzung KW, Williams RM, Scherer S, Federspiel N, Jones T, et al. 2001. Genomic evidence for a complete sexual cycle in Candida albicans. Proc. Natl. Acad. Sci. USA 98:3249-53
128. Vanden Bossche H, Dromer F, Improvisi I, Lozano CM, Rex JH, Sanglard D. 1998. Antifungal drug resistance in pathogenic fungi. Med. Mycol. Suppl. 1:119-28
129. Vanden Bossche H, Willemsens G, Marichal P. 1987. Anti-Candida drugs - The biochemical basis for their activity. Crit. Rev. Microbiol. 15:57-72
130. Verduyn Lunel FM, Meis JF, Voss A. 1999. Nosocomial fungal infections: Candidemia. Diagn. Microbiol. Infect. Dis. 34:213-20
131. Vilgalys R, Gräser Y, Schönian G, Presber W. 1997. Response to Tibayrenc. Trends Microbiol. 5:254-57
132. Voss A, Pfaller MA, Hollis RJ, RhineChalberg J, Doebbeling BN. 1995. Investigation of Candida albicans transmission in a surgical intensive care unit cluster by using genomic DNA typing methods. J. Clin. Microbiol. 33:576-80
133. Wahl LM, Krakauer DC. 2000. Models of experimental evolution: The role of genetic chance and selective necessity. Genetics 156:1437-48
134. Walsh TJ, Viviani MA, Arathoon E, Chiou C, Ghannoum M, et al. 2000. New targets and delivery systems for antifungal therapy. Med. Mycol. 38:335-47
135. White KP. 2001. Functional genomics and the study of development, variation and evolution. Nat. Rev. Genet. 2:528-37
136. White TC, Marr KA, Bowden RA. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402
137. Whiteway M. 2000. Transcriptional control of cell type and morphogenesis in Candida albicans. Curr. Opin. Microbiol. 3:582-88
138. Wichman HA, Badgett MR, Scott LA, Boulianne CM, Bull JJ. 1999. Different trajectories of parallel evolution during viral adaptation. Science 285:422-24
139. Wichman HA, Scott LA, Yarber CD, Bull JJ. 2000. Experimental evolution recapitulates natural evolution. Philos. Trans. R. Soc. London Ser. B 355:1677-84
140. Wloch DM, Szafraniec K, Borts RH, Korona R. 2001. Direct estimate of the mutation rate and the distribution of fitness effects in the yeast Saccharomyces cerevisiae. Genetics 159:441-52
141. Xu J, Boyd CM, Livingston E, Meyer W, Madden JF, Mitchell TG. 1999. Species and genotypic diversities and similarities of pathogenic yeasts colonizing women. J. Clin. Microbiol. 37:3835-43
142. Xu J, Mitchell TG, Vilgalys R. 1999. PCR-restriction fragment length polymorphism (RFLP) analyses reveal both extensive clonality and local genetic differences in Candida albicans. Mol. Ecol. 8:59-73
143. Xu J, Ramos AR, Vilgalys R, Mitchell TG. 2000. Clonal and spontaneous origins of fluconazole resistance in Candida albicans. J. Clin. Microbiol. 38:1214-20
144. Xu J, Vilgalys R, Mitchell TG. 1999. Lack of genetic differentiation between two geographically diverse samples of Candida albicans isolated from patients infected with human immunodeficiency virus. J. Bacteriol. 181:1369-73
145. Zeyl C. 2000. Budding yeast as a model organism for population genetics. Yeast 16:773-84
146. Zeyl C, DeVisser JA. 2001. Estimates of the rate and distribution of fitness effects of spontaneous mutation in Saccharomyces cerevisiae. Genetics 157:53-61
147. Zeyl C, Mizesko M, de Visser JA. 2001. Mutational meltdown in laboratory yeast populations. Evolution 55:909-17